change control – Page 29

Nitrosamine risk assessment incomplete during supplier audit – inspection-ready justification

Navigating Incomplete Nitrosamine Risk Assessments During Supplier Audits The increasing scrutiny of nitrosamines in pharmaceutical manufacturing is prompting organizations to reassess their risk management strategies, particularly during supplier audits. A…

Analytical method sensitivity questioned during supplier audit – risk mitigation and control strategy

Risk Mitigation and Control Strategies for Analytical Method Sensitivity Issues Highlighted During Supplier Audits Pharmaceutical manufacturing professionals often face challenges when analytical methods used for raw material assessments are deemed…

Risk mitigation plan inadequate during ongoing surveillance – CAPA for nitrosamine findings

Actionable Strategies for Inadequate Risk Mitigation Plans During Ongoing Surveillance of Nitrosamine Findings In the complex landscape of pharmaceutical manufacturing, the presence of nitrosamines in raw materials poses significant challenges.…

Risk mitigation plan inadequate during risk assessment – FDA/EMA nitrosamine expectations

Addressing Inadequate Risk Mitigation Plans During Nitrosamine Risk Assessments The increasing scrutiny surrounding nitrosamines in pharmaceutical products necessitates robust risk assessment and mitigation strategies. When a risk mitigation plan is…

Supplier nitrosamine control weak during submission support – CAPA for nitrosamine findings

Addressing Weak Supplier Nitrosamine Control During Submission Support: A Comprehensive Playbook The increasing scrutiny of nitrosamine impurities in pharmaceuticals has led to heightened expectations for supplier control measures. Regulatory bodies…

Potential nitrosamine source identified during regulatory inspection – CAPA for nitrosamine findings

Actionable Guide for Managing Nitrosamine Risks Uncovered in Regulatory Inspections In the highly regulated landscape of pharmaceutical manufacturing, the identification of potential nitrosamine sources during regulatory inspections poses a significant…

Regulatory query on nitrosamines during risk assessment – preventing product recall

Managing Regulatory Queries on Nitrosamines During Risk Assessment to Prevent Product Recall The detection of nitrosamines in pharmaceutical products has led to increased scrutiny from regulators such as the FDA,…

Analytical method sensitivity questioned during risk assessment – FDA/EMA nitrosamine expectations

Optimizing Analytical Method Sensitivity for Nitrosamine Risk Assessment Nitrosamines continue to be a point of sensitivity in the pharmaceutical sector, creating challenges in raw material management and quality control. As…

Nitrosamine risk assessment incomplete during supplier audit – FDA/EMA nitrosamine expectations

Nitrosamine Risk Assessment During Supplier Audits: Ensuring Completeness for Compliance Nitrosamine contamination has emerged as a critical quality issue, prompting heightened scrutiny from regulatory agencies such as the FDA and…

Nitrosamine risk assessment incomplete during regulatory inspection – FDA/EMA nitrosamine expectations

Navigating FDA and EMA Expectations for Nitrosamine Risk Assessments During Inspections The pharmaceutical industry faces increasing scrutiny regarding the presence of nitrosamines in drug products, particularly during regulatory inspections. Inadequate…

Nitrosamine risk assessment incomplete during ongoing surveillance – preventing product recall

Navigating Incomplete Nitrosamine Risk Assessments during Ongoing Surveillance to Prevent Product Recalls Nitrosamines have emerged as a critical concern in pharmaceutical manufacturing, especially given their potential to form during the…

Nitrosamine risk assessment incomplete during risk assessment – risk mitigation and control strategy

Strategies for Addressing Incomplete Nitrosamine Risk Assessments in Pharmaceutical Manufacturing Nitrosamines pose a significant risk in pharmaceutical manufacturing, particularly concerning the use of certain raw materials. When nitrosamine risk assessment…